Marie-Josephe Horner

Marie-Josephe Horner

Auto-generated profile, based on publicly available information

Marie-Josephe Horner

National Cancer Institute , Bethesda, Maryland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 May 2024 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JMJennifer K McGee-Avila
Jennifer K McGee-Avila
GSGita Suneja
Gita Suneja
EEEric A. Engels
Eric A. Engels
ARAnne F. Rositch
Anne F. Rositch
MHMarie-Josephe Horner
Marie-Josephe Horner
Jessica IslamJessica Islam
Jessica Islam
PURPOSE: People with HIV (PWH) have worse cancer outcomes, partially because of inequities in cancer treatment. We evaluated cancer treatment disparities among PWH, including an assessment of changes in disparities over time.METHODS: We used data from the HIV/AIDS Cancer Match Study, a population-based HIV and cancer registry linkage to examine diffuse large B-cell lymphoma (DLBCL), Hodgkin lymphoma (HL), and cancers of the cervix, lung, anus, prostate, colon, and female breast. Outcomes included receipt of (1) any cancer treatment and (2) standard therapy among patients with local-stage cancer. We assessed associations between HIV and each outcome by estimating adjusted prevalence odds ratios (aORs) with 95% CI and trends over time. We identified predictors of nonreceipt of cancer treatment in PWH.RESULTS: From 2001 to 2019, compared with people with cancer without HIV (n = 2,880,955), PWH (n = 16,334) were more likely to not receive cancer treatment for cervical cancer (aOR, 2.03 [95% CI, 1.52 to 2.70]), DLBCL (aOR, 1.53 [95% CI, 1.38 to 1.70]), HL (aOR, 1.39 [95% CI, 1.19 to 1.63]), lung cancer (aOR, 1.79 [95% CI, 1.65 to 1.93]), prostate cancer (aOR, 1.32 [95% CI, 1.21 to 1.44]), colon cancer (aOR, 1.73 [95% CI, 1.43 to 2.08]), and breast cancer (aOR, 1.38 [95% CI, 1.07 to 1.77]). Similar associations were observed in PWH with local-stage cancers although no difference was observed for anal cancers. The association between HIV and nonreceipt of cancer treatment significantly decreased over time for breast, colon, and prostate cancers (all P trend <.0001), but PWH remained less likely to receive treatment in 2014-2019 for DLBCL, cervix, and lung cancers. Among PWH, Black individuals, people who inject drugs, and those 65 years and older were less likely to receive cancer treatment.CONCLUSION: Disparities in receipt of cancer treatment persist for PWH in the United States in contemporary time periods. Solutions to address inequitable receipt of cancer treatment among PWH are urgently needed.

23 June 2021 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
PDF file
SPSally Peprah
Sally Peprah
EEEric A. Engels
Eric A. Engels
MHMarie-Josèphe Horner
Marie-Josèphe Horner
AMAnalise Monterosso
Analise Monterosso
HHH. Irene Hall
H. Irene Hall
MSMeredith S. Shiels
Meredith S. Shiels
Background: The introduction of combination antiretroviral therapy (cART) has led to a significant reduction in Kaposi sarcoma (KS) incidence among people with HIV (PWH). However, it is unclear if incidence has declined similarly across key demographic and HIV transmission groups and the annual number of incident and prevalent KS cases remains unquantified. Methods: Using population-based registry linkage data, we evaluated temporal trends in KS incidence using adjusted Poisson regression. Incidence and prevalence estimates were applied to CDC HIV surveillance data, to obtain the number of incident (2008–2015) and prevalent (2015) cases in the United States. Results: Among PWH, KS rates were elevated 521-fold [95% confidence intervals (CI), 498–536] compared with the general population and declined from 109 per 100,000 person-years in 2000 to 47 per 100,000 person-years in 2015, at an annual percentage change of −6%. Rates declined substantially (Ptrend < 0.005) across all demographic and HIV transmission groups. Of the 5,306 new cases estimated between 2008 and 2015, 89% occurred among men who have sex with men. At the end of 2015, 1,904 PWH (0.20%) had been diagnosed with KS in the previous 5 years. Conclusions: A consistent gradual decline in KS incidence has occurred among PWH in the United States during the current cART era. This decrease is uniform across key demographic and HIV transmission groups, though rates remain elevated relative to the general population. Impact: Continued efforts to control HIV through early cART initiation and retention in care need to be maintained and possibly expanded to sustain declines.

30 January 2014 in Journal of Community Health
Verified
Journal Article
Closed access
PDF file
LELindsey Enewold
Lindsey Enewold
MHMarie-Josèphe Horner
Marie-Josèphe Horner
CSCraig Shriver
Craig Shriver
KZKangmin Zhu
Kangmin Zhu

7 October 2022 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YLYen T. Luu
Yen T. Luu
QLQianlai Luo
Qianlai Luo
MHMarie-Josephe Horner
Marie-Josephe Horner
MSMeredith Shiels
Meredith Shiels
EEEric A. Engels
Eric A. Engels
MSMichael R. Sargen
Michael R. Sargen

18 March 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
ATAleah L. Thomas
Aleah L. Thomas
JRJongeun Rhee
Jongeun Rhee
JFJared A. Fisher
Jared A. Fisher
MHMarie-Josephe Horner
Marie-Josephe Horner
RJRena R. Jones
Rena R. Jones
Background: Greenspace is hypothesized as being protective against cancer, whereas noise pollution and fine particulate matter (<2.5 μm in diameter, PM2.5) are both potential risk factors. Findings from recent studies of greenspace and PM2.5 with prostate cancer are not conclusive and the association between noise exposure and cancer has not been evaluated in a U.S. study. Methods: We assessed PM2.5, noise, and greenspace exposure using spatiotemporal models and satellite-based estimates at enrollment addresses for N = 43,184 male participants of the prospective Prostate, Lung, Colorectal, and Ovarian Cancer (PLCO) Screening Trial cohort (enrolled 1994–2001). We used Cox regression models adjusted for age, race and ethnicity, study center, family history of prostate cancer, and Area Deprivation Index to estimate associations between ambient PM2.5 (μg/m3), greenspace (index range from –1 to 1), and noise pollution (loudest 10% of total existing sound, decibels) and incident prostate cancer risk through December 2017. Results: A total of 6,327 cases of prostate cancer were diagnosed among male participants during follow-up. PM2.5 and noise exposures were moderately positively correlated (Spearman ρ = 0.46), and PM2.5 and greenspace were not correlated (ρ = 0.10); greenspace and noise were inversely correlated (ρ = −0.32). In single-pollutant and multipollutant models mutually adjusted for coexposures, we found no associations with prostate cancer risk. Conclusions: We did not find evidence that PM2.5, greenspace, and noise pollution were associated with prostate cancer risk in this large, geographically spread cohort. Impact: This study contributes to a small body of existing literature investigating these biologically plausible associations.

7 November 2024 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
QLQianlai Luo
Qianlai Luo
MHMarie-Josèphe Horner
Marie-Josèphe Horner
CHCameron Brady Haas
Cameron Brady Haas
JMJennifer K McGee-Avila
Jennifer K McGee-Avila
RPRuth M Pfeiffer
Ruth M Pfeiffer
MSMeredith S Shiels
Meredith S Shiels
Background: It is unclear whether cancer risk among people with human immunodeficiency virus (HIV, PWH) has declined equally across all racial/ethnic and transmission risk groups. Methods: We used data on PWH aged ≥20 years from the HIV/AIDS Cancer Match Study during 2001–2019. We used Poisson regression to assess time trends in incidence rates for each cancer site by racial/ethnicity and risk groups, adjusting for age, registry, and sex. We also estimated adjusted rate ratios across racial and ethnic and risk groups in 2001–2004 and 2015–2019. Results: Trends in age-standardized rates differed across racial/ethnic groups and across risk groups for some cancers. For example, liver cancer rates declined 23% per 5-year period among White PWH, 11% among Black PWH, and 18% among Hispanic PWH. Anal cancer rates declined among men who have sex with men, were stable among people who inject drugs, and increased among other risk groups. Between 2001–2004 and 2015–2019, the relative difference in cancer incidence rates by race/ethnicity increased for Hodgkin lymphoma (HL) and liver cancer but decreased for non-Hodgkin lymphoma (NHL); by risk group, relative differences increased for NHL and liver cancer and decreased for HL and lung and anal cancers. Conclusions: Among PWH in the United States during 2001–2019, HL, lung, liver, and cervical cancer rate trends were different across racial/ethnic groups. HL, lung, anal, and liver cancer rate trends were different across risk groups. Future work should examine underlying causes of the differences in trends.